XML 91 R116.htm IDEA: XBRL DOCUMENT
v3.19.3.a.u2

Collaborative and Other Relationships - Genentech (Details) - USD ($) $ in Millions | 3 Months Ended | 12 Months Ended |  |
--- | --- | --- | --- | ---
Dec. 31, 2019 | Sep. 30, 2019 | Jun. 30, 2019 | Mar. 31, 2019 | Dec. 31, 2018 | Sep. 30, 2018 | Jun. 30, 2018 | Mar. 31, 2018 | Dec. 31, 2019 | Dec. 31, 2018 | Dec. 31, 2017 | Sep. 30, 2017 | Mar. 31, 2016
Revenues from unconsolidated joint business |  |  |  |  |  |  |  |  |  |  |  |  |
Total revenues from anti-cd20 therapeutic programs | $ 3,671.3 | $ 3,600.1 | $ 3,616.7 | $ 3,489.8 | $ 3,526.3 | $ 3,439.0 | $ 3,356.5 | $ 3,131.1 | $ 14,377.9 | $ 13,452.9 | $ 12,273.9 |  |
Genentech |  |  |  |  |  |  |  |  |  |  |  |  |
Revenues from unconsolidated joint business |  |  |  |  |  |  |  |  |  |  |  |  |
Biogen's share of pre-tax profits in the U.S. for RITUXAN and GAZYVA, including the reimbursement of selling and development expenses |  |  |  |  |  |  |  |  | 1,542.4 | 1,431.9 | 1,316.4 |  |
Other revenues from anti-CD20 therapeutic programs |  |  |  |  |  |  |  |  | $ 748.0 | $ 548.3 | $ 242.8 |  |
GAZYVA |  |  |  |  |  |  |  |  |  |  |  |  |
After First GA101 Threshold Date |  |  |  |  |  |  |  |  |  |  |  |  |
Until First GAZYVA Threshold Date | 39.00% |  |  |  |  |  |  |  | 39.00% |  |  |  |
After First Threshold Date and until Second Threshold Date | 37.50% |  |  |  |  |  |  |  | 37.50% |  |  |  |
After Second Threshold Date | 35.00% |  |  |  |  |  |  |  | 35.00% |  |  |  |
RITUXAN |  |  |  |  |  |  |  |  |  |  |  |  |
Co-promotion profit sharing formula |  |  |  |  |  |  |  |  |  |  |  |  |
Until GAZYVA First Non-CLL FDA Approval | 40.00% |  |  |  |  |  |  |  | 40.00% |  |  |  |
After First GA101 Threshold Date |  |  |  |  |  |  |  |  |  |  |  |  |
Until First GAZYVA Threshold Date | 39.00% |  |  |  |  |  |  |  | 39.00% |  | 37.50% |  | 39.00%
After First Threshold Date and until Second Threshold Date | 37.50% |  |  |  | 37.50% |  |  |  | 37.50% | 37.50% |  | 37.50% |
After Second Threshold Date | 35.00% |  |  |  |  |  |  |  | 35.00% |  |  |  |
Revenues from anti-cd20 therapeutic programs |  |  |  |  |  |  |  |  |  |  |  |  |
Revenues from unconsolidated joint business |  |  |  |  |  |  |  |  |  |  |  |  |
Total revenues from anti-cd20 therapeutic programs | $ 600.8 | $ 595.8 | $ 576.4 | $ 517.4 | $ 534.9 | $ 511.7 | $ 490.4 | $ 443.2 | $ 2,290.4 | $ 1,980.2 | $ 1,559.2 |  |

X
- Definition Co-promotion profit sharing formula. + References No definition available. + Details
Name: | biib_CoPromotionProfitSharingFormulaAbstract
Namespace Prefix: | biib_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Other revenues from anti-CD20 therapeutic programs consists of revenue on sales of RITUXAN outside the U.S., which consist of our share of pre-tax co-promotion profits in Canada and royalty revenue on sales of Ocrevus. + References No definition available. + Details
Name: | biib_OtherrevenuesfromantiCD20therapeuticprograms
Namespace Prefix: | biib_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Percentage of co promotion operating profits greater than first fifty million option one. + References No definition available. + Details
Name: | biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionOne
Namespace Prefix: | biib_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Percentage of co promotion operating profits greater than first fifty million option two. + References No definition available. + Details
Name: | biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoAbstract
Namespace Prefix: | biib_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Percentage of co promotion operating profits greater than first fifty million option two sub option one. + References No definition available. + Details
Name: | biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne
Namespace Prefix: | biib_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Percentage of co promotion operating profits greater than first fifty million option two sub option three. + References No definition available. + Details
Name: | biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree
Namespace Prefix: | biib_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Percentage of co promotion operating profits greater than first fifty million option two sub option two. + References No definition available. + Details
Name: | biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo
Namespace Prefix: | biib_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Revenues from unconsolidated joint business. + References No definition available. + Details
Name: | biib_RevenuesFromUnconsolidatedJointBusinessAbstract
Namespace Prefix: | biib_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Share of co promotion profits. + References No definition available. + Details
Name: | biib_ShareOfCoPromotionProfits
Namespace Prefix: | biib_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss). + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8933-108599 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(1)) -URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227 + Details
Name: | us-gaap_Revenues
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | srt_MajorCustomersAxis=biib_RocheGroupGenentechMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=biib_GAZYVAMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=biib_RituxanMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=biib_Revenuesfromanticd20therapeuticprogramsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |